Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

и другие.

Biomolecules, Год журнала: 2024, Номер 14(11), С. 1479 - 1479

Опубликована: Ноя. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Язык: Английский

Impact of SGLT2 Inhibitors on Survival in Gastrointestinal Cancer Patients Undergoing Chemotherapy and/or Radiotherapy: A Real-World Data Retrospective Cohort Study DOI Open Access
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Янв. 12, 2025

Abstract Background The role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) drugs in the management diabetes and cardiovascular disease is well-established, but emerging evidence suggests potential effects on cancer outcomes, including gastrointestinal (GI) cancers. We conducted an extensive, sex-oriented, real-world data analysis to investigate whether SGLT2i can enhance GI outcomes when used alongside standard therapies such as chemotherapy radiotherapy. Methods study applied a retrospective cohort design with from TriNetX research database ( https://trinetx.com ), examining patients treated and/or radiotherapy between 2013 2023. intervention consisted Gl who received SGLT2i, while control did not. A 5-year follow-up period was used, baseline characteristics were balanced using 1:1 propensity score matching technique. Cox proportional-hazards logistic regression models assessed mortality morbidity risks cohorts. Results included 6,389 male 3,457 female (ICD-10: C15-C25). use significantly associated improved survival for both (HR 0.568; 95% CI 0.534-0.605) 0.561; 0.513-0.614) undergoing also correlated lower hospitalisation rates (OR 0.684; 0.637-0.734) (OR, 0.590; 0.536-0.650) patients. subtypes demonstrated similar benefits, without significant adverse effects. Conclusions Repurposing SGLT2 inhibitors treatment could potentially improve causing side Further clinical trials are needed confirm these findings establish optimal condition its application treatment.

Язык: Английский

Процитировано

0
Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study DOI Creative Commons
Lucas E. Flausino, Alexis Germán Murillo Carrasco, Tatiane Katsue Furuya

и другие.

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Март 25, 2025

The role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) drugs in the management diabetes and cardiovascular disease is well-established, but emerging evidence suggests potential effects on cancer outcomes, including gastrointestinal (GI) cancers. We conducted an extensive, sex-oriented, real-world data analysis to investigate whether SGLT2i can enhance GI outcomes when used alongside standard therapies such as chemotherapy radiotherapy. study applied a retrospective cohort design with from TriNetX research database ( https://trinetx.com ), examining patients treated and/or radiotherapy between 2013 2023. intervention consisted Gl who received SGLT2i, while control did not. A 5-year follow-up period was used, baseline characteristics were balanced using 1:1 propensity score matching technique. Cox proportional-hazards logistic regression models assessed mortality morbidity risks cohorts. included 6,389 male 3,457 female (ICD-10: C15-C25). use significantly associated improved survival for both (HR 0.568; 95% CI 0.534–0.605) 0.561; 0.513–0.614) undergoing also correlated lower hospitalisation rates (OR 0.684; 0.637–0.734) (OR, 0.590; 0.536–0.650) patients. subtypes demonstrated similar benefits, without significant adverse effects. Repurposing SGLT2 inhibitors treatment could potentially improve causing side Further clinical trials are needed confirm these findings establish optimal condition its application treatment.

Язык: Английский

Процитировано

0
Dysregulation of deubiquitinases in gastric cancer progression DOI Creative Commons

Zifan Xu,

Zi Lei,

Shilan Peng

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Ноя. 13, 2024

Gastric cancer (GC), characterized by a high incidence rate, poses significant clinical challenges owing to its poor prognosis despite advancements in diagnostic and therapeutic approaches. Therefore, comprehensive understanding of the molecular mechanisms driving GC progression is crucial for identifying predictive markers defining treatment targets. Deubiquitinating enzymes (DUBs), also called deubiquitinases, function as reverse transcriptases within ubiquitin-proteasome system counteract protein degradation. Recent findings suggest that DUB dysregulation could be factor pathogenesis. In this review, we examined recent research on DUBs context GC, elucidating their characteristics, categorizations, roles while exploring potential underlying GC. Furthermore, assessed efficacy inhibitors treating malignancies evaluated prevalence aberrant expression

Язык: Английский

Процитировано

0
Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

и другие.

Biomolecules, Год журнала: 2024, Номер 14(11), С. 1479 - 1479

Опубликована: Ноя. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Язык: Английский

Процитировано

0